Inventiva Secures $120M Equity Offering & €130M Debt to Extend Runway Ahead of Phase 3 Readout
IVA sits 51% above its 52-week low of $2.854 on elevated volume (7.3× avg).
Summary
Inventiva S.A. announced a comprehensive capital structure optimization, including a $120 million equity offering and up to €130 million in new debt, to extend its cash runway and address prior 'going concern' warnings ahead of a critical Phase 3 readout.
Key Events · Financing and Capital Events · IVA
-
Secured $120 Million Equity Offering
The company priced an underwritten offering of 27,272,727 American Depositary Shares (ADSs) at $4.40 per ADS, generating approximately $110.8 million in net proceeds. This offering was conducted under the F-3ASR shelf registration filed today.
-
Obtained Up to €130 Million New Debt Financing
Inventiva secured a new debt facility with BlackRock and Claret Capital Partners for up to €130 million in committed tranches, plus an additional uncommitted €20 million. This replaces the existing EIB loan and extends the debt maturity profile to 2030, with an initial aggregate drawdown of €75 million.
-
Restructured EIB Warrants to Reduce Dilution
The company agreed to repurchase approximately 60% of its existing dilution-protected EIB warrants (equivalent to ~22.7 million shares) for €50 million at a 40% discount to intrinsic value. The remaining EIB warrants will be restructured into new warrants without anti-dilution provisions, significantly mitigating future dilution risk.
-
Extended Cash Runway into Early 2028
The combined transactions are expected to extend Inventiva's cash runway into early first quarter 2028, assuming the full exercise of Tranche 3 warrants from a previous structured financing. This addresses the company's prior 'going concern' warnings.
Analysis · IVA · Life Sciences
Inventiva S.A. has executed a comprehensive financing package that directly addresses its previously disclosed 'going concern' warning and severe financial distress. This critical capital raise, combining a $120 million equity offering and up to €130 million in new debt, extends the company's cash runway into early Q1 2028. While the equity offering is dilutive, and the new debt comes with stringent covenants, including security interests over key patents and default clauses tied to Phase 3 trial success, this transaction is essential for the company's survival and its ability to fund operations through the anticipated Phase 3 readout in Q4 2026. The restructuring of highly dilutive EIB warrants also improves the long-term capital structure.
At the time of this filing, IVA was trading at $4.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $2.85 to $7.98. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.